ABBOTT LABORATORIES 8K

Abbott Laboratories reported strong Q2 2026 results, raised its full-year adjusted EPS guidance, detailed progress on key medical technologies, and declared its 410th consecutive quarterly dividend.

Abbott Laboratories filed a Form 8-K to furnish its Q2 2026 earnings release, reporting 13.0% year-over-year growth in net sales to $12.6 billion, GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.31, alongside reaffirmed full-year 2026 comparable sales growth guidance of 6.5%–7.5% and a raised full-year adjusted EPS guidance range of $5.45–$5.60. The company highlighted segment performance, including strong growth in Diagnostics and Medical Devices, integration of the March 23, 2026 acquisition of Exact Sciences into its Cancer Diagnostics business, and various product, clinical, and regulatory milestones such as completion of enrollment in the TECTONIC U.S. pivotal IVL trial, new electrophysiology data presented at HRS, CE Mark for the Libre Duo dual glucose-ketone sensor, and FDA submission for the Amulet 360 LAA device. Abbott also disclosed that it returned $2.1 billion to shareholders through dividends and share repurchases in the quarter, and that its board declared a $0.63 per share quarterly dividend payable August 17, 2026, marking the company’s 410th consecutive quarterly dividend and continuing its 54-year streak of dividend increases.

Filing Facts

CIK

1800

Ticker

ABT

Form

8K

Source Type

sec

Accession

0001628280-26-048377

Alert Tier

7